Paradigm

Acrivon Therapeutics Announces $130 Million Private Placement Financing

Retrieved on: 
Mardi, avril 9, 2024
ACRV, Exchange, Health, Intelligence, Patient, Neoplasm, Paradigm, Research, AP3, Sale, Security (finance), Prospectus, Investment, Therapy, PIPE, Jefferies, Machine learning, Medicine

Acrivon anticipates the gross proceeds from the oversubscribed PIPE to be approximately $130 million, before deducting fees to the placement agent and other offering expenses payable by the company.

Key Points: 
  • Acrivon anticipates the gross proceeds from the oversubscribed PIPE to be approximately $130 million, before deducting fees to the placement agent and other offering expenses payable by the company.
  • The closing of the financing is expected to occur on April 11, 2024, subject to customary closing conditions.
  • “We are excited to announce this financing and thank our new and key existing investors who have shown their support for and confidence in Acrivon,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
  • Jefferies acted as the exclusive placement agent in the private placement.

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

Retrieved on: 
Mercredi, avril 3, 2024
Paragon, Freedom, Psoriasis, Biotechnology, ARCA, Disease, Patient, Paradigm, Psoriatic arthritis, Standard of care, Doctor of Philosophy, Investment, RTW, Engineering, Pharmaceutical industry

WESTMINSTER, Colo. and WALTHAM, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”), and Oruka Therapeutics (“Oruka”), a privately held biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, announced today that they have entered into a definitive agreement to combine the companies in an all-stock transaction. The resulting entity will focus on advancing Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) and ORKA-002 (an IL-17A/F inhibitor). Upon completion of the merger, the combined company plans to operate under the name Oruka Therapeutics, Inc. and trade on Nasdaq under the ticker symbol “ORKA”.

Key Points: 
  • Upon completion of the merger, the combined company plans to operate under the name Oruka Therapeutics, Inc. and trade on Nasdaq under the ticker symbol “ORKA”.
  • In addition, prior to closing of the merger, ARCA expects to declare a cash dividend to the pre-merger ARCA stockholders equal to the amount by which ARCA’s net cash exceeds $5 million.
  • “Our mission at Oruka is to offer people affected with chronic skin diseases the most possible freedom from their condition.
  • Oruka is the third company founded based on assets generated by Paragon Therapeutics (“Paragon”).

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

Retrieved on: 
Mercredi, avril 3, 2024
Paragon, Freedom, Psoriasis, Biotechnology, ARCA, Disease, Patient, Paradigm, Psoriatic arthritis, Standard of care, Doctor of Philosophy, Investment, RTW, Engineering, Pharmaceutical industry

WESTMINSTER, Colo. and WALTHAM, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”), and Oruka Therapeutics (“Oruka”), a privately held biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, announced today that they have entered into a definitive agreement to combine the companies in an all-stock transaction. The resulting entity will focus on advancing Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) and ORKA-002 (an IL-17A/F inhibitor). Upon completion of the merger, the combined company plans to operate under the name Oruka Therapeutics, Inc. and trade on Nasdaq under the ticker symbol “ORKA”.

Key Points: 
  • Upon completion of the merger, the combined company plans to operate under the name Oruka Therapeutics, Inc. and trade on Nasdaq under the ticker symbol “ORKA”.
  • In addition, prior to closing of the merger, ARCA expects to declare a cash dividend to the pre-merger ARCA stockholders equal to the amount by which ARCA’s net cash exceeds $5 million.
  • “Our mission at Oruka is to offer people affected with chronic skin diseases the most possible freedom from their condition.
  • Oruka is the third company founded based on assets generated by Paragon Therapeutics (“Paragon”).

Proprio Announces Strategic Partnership with Biedermann to Revolutionize Surgery Through AI-Powered Guidance

Retrieved on: 
Mardi, avril 9, 2024
Partnership, Patient, Paradigm, 3D, Radiation exposure, AI, Surgeon, Workflow, Health, Medical device

SEATTLE, April 9, 2024 /PRNewswire/ -- Proprio, the leader in AI-powered surgical technology, today announced a landmark multi-phase partnership with the Biedermann Group,  the prominent innovator in next generation spinal implant systems and procedural solutions. Initially, the companies will collaborate to integrate Biedermann's advanced spinal implants with Proprio's Paradigm system, which harnesses AI, computer vision, and augmented reality to provide unprecedented real-time visualization and guidance to surgeons in the operating room.

Key Points: 
  • By capturing and analyzing vast amounts of data, Paradigm aims to dramatically improve surgical precision, workflow, decision-making, and ultimately patient outcomes.
  • Proprio's initial focus on spinal surgery is driven by the immense need for technological advancements in this field.
  • "This collaboration with Biedermann will further increase the Paradigm platform's unique capabilities to positively impact patient results through data-based planning and performance.
  • We are excited to accelerate this critical partnership with Biedermann so that clinicians and patients alike can benefit from our advanced surgical guidance capabilities," said Gabriel Jones, CEO and Co-founder of Proprio.

Paradigm by Puloli™ Transforms Methane Monitoring with its Solution-as-a-Service (SaaS)

Retrieved on: 
Mardi, avril 9, 2024
TDLAS, Internet of things, SAN, M series, Paradigm, Software, Workflow, Software as a service, Data collection, Methane, Video game

The M-Series is a perfect product-market fit for Puloli's networking solution vertically integrated with IoT applications in methane monitoring-as-a-service.

Key Points: 
  • The M-Series is a perfect product-market fit for Puloli's networking solution vertically integrated with IoT applications in methane monitoring-as-a-service.
  • Paradigm uses state-of-the-art TDLAS methane sensors, anemometers, and edge compute devices to guarantee top-quality components for seamless workflow and data collection.
  • Performance expectations are shifting in methane monitoring, and Paradigm by Puloli™ stands at the forefront with its M-Series™.
  • By addressing the industry's pain points, Paradigm has modernized methane monitoring and redefined the standards of accuracy, reliability, and cost-effectiveness.

Obsidian Therapeutics Announces Oversubscribed $160.5 Million Series C Financing to Drive OBX-115 Clinical Development

Retrieved on: 
Mercredi, avril 3, 2024
Biotechnology, Health, Genetics, Clinical Trials, Oncology, Janus, Growth, Novo Holdings A/S, NSCLC, TIL, Patient, Wellington Management Company, Paradigm, Foresite Capital, Bristol Myers Squibb, Lung cancer, Doctor of Philosophy, Therapy, Melanoma, Investment, Atlas Venture, Pharmaceutical industry

Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a significantly oversubscribed $160.5 million Series C financing with a top-tier syndicate of life science investors led by new investor, Wellington Management.

Key Points: 
  • Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a significantly oversubscribed $160.5 million Series C financing with a top-tier syndicate of life science investors led by new investor, Wellington Management.
  • Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC).
  • The Company is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.
  • “This financing provides funding through key clinical readouts in melanoma and is the catalyst to continue expanding OBX-115 into NSCLC, where there is significant potential and high unmet need.”

Blastoise: The Official Mascot Meme Coin of Blast - Unveiling the Future of L2 Finance

Retrieved on: 
Lundi, mars 4, 2024
Bitconnect, Turtle, API, Royale, NFT, ETH, OSF, DEX, Ecosystem, Paradigm, Imagination, TCG, Decentralized finance, Cryptocurrency

It stands out in the meme coin space, which is often driven by hype and community engagement.

Key Points: 
  • It stands out in the meme coin space, which is often driven by hype and community engagement.
  • Firstly, the meme coin market is known for repetitive designs, with numerous dog-themed memes flooding the market and needing more imagination.
  • This ensures an active community of users that are invested in its ecosystem beyond the thrill of just owning a meme coin.
  • Lastly, Six weeks after its debut, Blastoise made a significant impact by collaborating with Bitconnect token, the official meme decentralized exchange (DEX) on Blast.

Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement

Retrieved on: 
Mercredi, février 28, 2024
Janus, Therapy, SAN, Research, Sale, Richard Driehaus, SVB Securities, Paradigm

Crinetics anticipates the gross proceeds from the private placement to be approximately $350 million, before deducting any offering-related expenses.

Key Points: 
  • Crinetics anticipates the gross proceeds from the private placement to be approximately $350 million, before deducting any offering-related expenses.
  • The private placement is expected to close on or about March 1, 2024, subject to the satisfaction of customary closing conditions.
  • Leerink Partners, Piper Sandler, Baird, Citizens JMP, H.C. Wainwright & Co., and LifeSci Capital are acting as placement agents to the Company in connection with the private placement.
  • Crinetics has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) registering the resale of the shares of common stock issued in the private placement no later than the 40th day after the pricing of the private placement.

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution

Retrieved on: 
Mercredi, février 28, 2024
Real-World Evidence, Cohort, KNSA, C-reactive protein, Rheumatoid factor, Recurrence, Investment, Telephone, Partnership, Growth, ID, Joint, Genentech, Roche, Rheumatoid arthritis, American College, Webcast, Patient, Pericarditis, Paradigm, Prescription, CD40, Pharmaceutical industry

HAMILTON, Bermuda, Feb. 28, 2024 (GLOBE NEWSWIRE) --  Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported fourth quarter and full-year 2023 financial results and recent portfolio execution.

Key Points: 
  • Total revenue for the fourth quarter of 2023 was $83.4 million, compared to $61.9 million for the fourth quarter of 2022.
  • Total operating expenses for the fourth quarter of 2023 were $83.3 million, compared to $55.8 million for the fourth quarter of 2022.
  • Net income for the fourth quarter of 2023 was $25.2 million, compared to net income of $4.5 million for the fourth quarter of 2022.
  • Kiniksa will host a conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, February 28, 2024, to discuss fourth quarter and full-year 2023 financial results and recent portfolio execution.

Avangrid Recognizes Pioneering Women Leaders on International Women’s Day

Retrieved on: 
Vendredi, mars 8, 2024
Environment, Women, Other Energy, Utilities, Oil, Gas, Alternative Energy, Sustainability, Energy, Consumer, Acquisition, International, Senior, Woman, AGR, Sustainable energy, Electricity, Natural gas, Female, International Energy Agency, Society, Paradigm, Parity, State, Workforce, Gender

Today, women make-up more than 27% of Avangrid’s approximate 8,000 employees and more than 35% of the company’s senior leadership positions1 are held by women.

Key Points: 
  • Today, women make-up more than 27% of Avangrid’s approximate 8,000 employees and more than 35% of the company’s senior leadership positions1 are held by women.
  • “At Avangrid, we’re committed to fostering a diverse and inclusive workplace that empowers women to reach their full potential.
  • I’m particularly proud to have so many talented women leaders on our team who are helping shape the future of our industry.”
    Since 2021 Avangrid has increased the number of women in its executive leadership team by 25%.
  • In addition to these initiatives, Avangrid has a business resource group—WomENergy—dedicated to increasing the visibility of women in the company.